Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Martec nifedipine XL

Executive Summary

"To the best of our knowledge...Mylan has only filed and obtained tentative approval for the 30 mg" strength of nifedipine extended-release, a generic form of Pfizer's Procardia XL, Martec Scientific states in a letter to "The Pink Sheet." Mylan received tentative approval for 30 mg nifedipine XL March 15. Martec noted it has filed for 30 mg, 60 mg and 90 mg tablets, and pointed out the "exclusivity status is not fully clear" for the different strengths ("The Pink Sheet" April 5, p. 10)

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel